Canaccord Genuity analyst William Plovanic has maintained their bullish stance on BSX stock, giving a Buy rating today.
William Plovanic has given his Buy rating due to a combination of factors that highlight Boston Scientific’s strong financial performance and strategic positioning. The company reported impressive first-quarter results for 2025, surpassing both Canaccord Genuity’s and consensus expectations in terms of revenue and earnings per share. This outperformance was driven by robust growth in the electrophysiology segment, particularly through the Farapulse system, and the continued success of the Watchman device.
Boston Scientific’s management has also raised its full-year 2025 guidance, demonstrating confidence in the company’s ability to maintain its leadership in the cardiovascular market despite potential challenges. The company anticipates a $200 million impact from tariffs but expects to mitigate this through increased organic sales, targeted spending reductions, and favorable foreign exchange effects. The strategic initiatives and operational excellence exhibited by Boston Scientific are reflected in the reaffirmed Buy rating and the price target of $117.
According to TipRanks, Plovanic is a 3-star analyst with an average return of 1.1% and a 43.70% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as TransMedics Group, CVRx, and Atricure.
In another report released today, Needham also reiterated a Buy rating on the stock with a $115.00 price target.